Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BMS225975

Known as: BMS-225975 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder maintained by cancer stem cells. To target this population… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Chronic myeloid leukemia (CML), a hematopoietic stem-cell disorder, cannot be eradicated by conventional chemotherapy or the… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2007
2007
Chronic myeloid leukemia (CML), a hematopoietic stem cell disorder, cannot be eradicated by conventional chemotherapy or the… Expand
  • table I
Is this relevant?
2007
2007
Chronic myeloid leukemia (CML), a hematopoietic stem cell disorder, cannot be eradicated by conventional chemotherapy or the… Expand
  • table I
Is this relevant?
2007
2007
Chronic myeloid leukemia (CML), a hematopoietic stem cell (HSC) disorder, cannot be eradicated by conventional chemotherapy or… Expand
  • table 1
Is this relevant?
2006
2006
3805 Sarcomas are a heterogeneous group of mesenchymal malignancies whose benefit from traditional chemotherapy has been… Expand
Is this relevant?
2005
2005
Farnesyltransferase inhibitors (FTI) have been developed as anticancer drugs and are currently being evaluated in clinical trials… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
2004
2004
BMS-214662 and BMS-225975 are tetrahydrobenzodiazepine-based farnesyltransferase inhibitors (FTIs) that have nearly identical… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?